Stockscreener 앱 받기
0.6304
5.90%
0.0351
시장 영업 전:
.60
-0.0304
-4.82%
전일 마감가:
$0.5953
열려 있는:
$0.59
하루 거래량:
1.11M
Relative Volume:
0.86
시가총액:
$49.87M
수익:
$153.73M
순이익/손실:
$-106.79M
주가수익비율:
-0.3542
EPS:
-1.78
순현금흐름:
$-115.93M
1주 성능:
-17.64%
1개월 성능:
-60.35%
6개월 성능:
-82.04%
1년 성능:
-87.61%
1일 변동 폭
$0.59
$0.6795
1주일 범위
$0.5815
$0.798
52주 변동 폭
$0.5815
$5.70
Sutro Biopharma Inc Stock (STRO) Company Profile
명칭
Sutro Biopharma Inc
전화
650-392-8412
주소
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
STRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
0.6304 | 49.87M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-05-08 | 개시 | BofA Securities | Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-06 | 개시 | Oppenheimer | Outperform |
| 2023-03-21 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2021-06-18 | 개시 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-07-16 | 개시 | Wells Fargo | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-10-07 | 개시 | BTIG Research | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2019-04-29 | 개시 | H.C. Wainwright | Buy |
| 2018-10-22 | 개시 | JMP Securities | Mkt Outperform |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
| 2018-10-22 | 개시 | Wedbush | Outperform |
모두보기
Sutro Biopharma Inc 주식(STRO)의 최신 뉴스
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Hold” from Analysts - Defense World
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa
Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Biotech company based in Peninsula laying off 90% of staff - MSN
HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World
Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media
Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN
Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com
Sutro Biopharma (NASDAQ:STRO) Cut to Market Perform at Citizens Jmp - Defense World
Array Technologies, Nextracker, Sutro Biopharma - TradingView
Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK
Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal
Sutro Biopharma Presents Promising Late-Stage Data for Luveltamab Tazevibulin in Platinum-Resistant Ovarian Cancer – Apnakal market - Apna Kal
Sutro Biopharma’s Luvelta Shows Promising Data in Late-Stage Ovarian Cancer Study at SGO 2025 - Apna Kal
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The Manila Times
Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future - StockTitan
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Yahoo Finance
Bay Area biotech company once worth $2B guts staff, departing execs get $600K - MSN
Sutro Biopharma Prioritizes ADC Programs Amid Financial Shift - TipRanks
Cattle Post Gains on Friday, Helped by Cah Strength - The Globe and Mail
Oppenheimer cuts Sutro Biopharma stock rating to Perform By Investing.com - Investing.com Canada
Oppenheimer cuts Sutro Biopharma stock rating to Perform - Investing.com India
Jefferies cuts Sutro Biopharma target to $8, maintains Buy By Investing.com - Investing.com Canada
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Longtime Peninsula biotech to chop half its jobs, CEO exitsSan Francisco Business Times - The Business Journals
Earnings call transcript: Sutro Biopharma Q4 2024 sees stock plunge - Investing.com India
Truist maintains Buy on Sutro Biopharma, removes price target By Investing.com - Investing.com UK
Sutro prioritizes preclinical ADC programs - BioWorld Online
Sutro stock drops as analysts downgrade (STRO:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Higher Premarket Friday -March 14, 2025 at 09:30 am EDT - Marketscreener.com
New ADC focus as Sutro slashes workforce, drops lead drug - The Pharma Letter
This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8 - Marketscreener.com
Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review - BioSpace
Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - TradingView
Sutro Biopharma Inc (STRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):